WO2002077034A3 - Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity - Google Patents

Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity Download PDF

Info

Publication number
WO2002077034A3
WO2002077034A3 PCT/EP2002/001171 EP0201171W WO02077034A3 WO 2002077034 A3 WO2002077034 A3 WO 2002077034A3 EP 0201171 W EP0201171 W EP 0201171W WO 02077034 A3 WO02077034 A3 WO 02077034A3
Authority
WO
WIPO (PCT)
Prior art keywords
csf
stimulating factor
colony stimulating
granulocyte colony
reduced immunogenicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/001171
Other languages
French (fr)
Other versions
WO2002077034A2 (en
Inventor
Francis J Carr
Graham Carter
Tim Jones
Stephen Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002437287A priority Critical patent/CA2437287A1/en
Priority to EP02727320A priority patent/EP1392731B1/en
Priority to JP2002576292A priority patent/JP2004527243A/en
Priority to MXPA03007002A priority patent/MXPA03007002A/en
Priority to US10/467,396 priority patent/US7392141B2/en
Priority to KR10-2003-7010307A priority patent/KR20030074785A/en
Priority to PL02363501A priority patent/PL363501A1/en
Priority to HU0402041A priority patent/HUP0402041A2/en
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to DE60227367T priority patent/DE60227367D1/en
Priority to BR0207020-0A priority patent/BR0207020A/en
Publication of WO2002077034A2 publication Critical patent/WO2002077034A2/en
Anticipated expiration legal-status Critical
Publication of WO2002077034A3 publication Critical patent/WO2002077034A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S707/00—Data processing: database and file management or data structures
    • Y10S707/99941—Database schema or data structure
    • Y10S707/99943—Generating database or data structure, e.g. via user interface

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Theoretical Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of granulocyte colony stimulating factor (G-CSF) to result in granulocyte colony stimulating factor (G-CSF) proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.
PCT/EP2002/001171 2001-02-06 2002-02-05 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity Ceased WO2002077034A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
PL02363501A PL363501A1 (en) 2001-02-06 2002-02-05 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
JP2002576292A JP2004527243A (en) 2001-02-06 2002-02-05 Modified granulocyte colony stimulating factor (G-CSF) with reduced immunogenicity
MXPA03007002A MXPA03007002A (en) 2001-02-06 2002-02-05 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity.
US10/467,396 US7392141B2 (en) 2001-02-06 2002-02-05 Method of preparing a modified granulocyte colony stimulating factor (G-CSF) with reduced immunogenicity
KR10-2003-7010307A KR20030074785A (en) 2001-02-06 2002-02-05 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
CA002437287A CA2437287A1 (en) 2001-02-06 2002-02-05 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
BR0207020-0A BR0207020A (en) 2001-02-06 2002-02-05 Reduced immunogenicity modified granulocyte colony stimulating factor (g-csf)
HU0402041A HUP0402041A2 (en) 2001-02-06 2002-02-05 Reduced immunogenicity, modified granulocyte colonization stimulating factor (G-CSF)
DE60227367T DE60227367D1 (en) 2001-02-06 2002-02-05 MODIFIED GRANULOCYTE STIMULATING FACTOR (G-CSF) WITH REDUCED IMMUNOGENITY
EP02727320A EP1392731B1 (en) 2001-02-06 2002-02-05 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01102617 2001-02-06
EP01102617.6 2001-02-06
EP01103954.2 2001-02-19
EP01103954 2001-02-19

Publications (2)

Publication Number Publication Date
WO2002077034A2 WO2002077034A2 (en) 2002-10-03
WO2002077034A3 true WO2002077034A3 (en) 2003-12-11

Family

ID=26076460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/001171 Ceased WO2002077034A2 (en) 2001-02-06 2002-02-05 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity

Country Status (15)

Country Link
US (1) US7392141B2 (en)
EP (1) EP1392731B1 (en)
JP (1) JP2004527243A (en)
KR (1) KR20030074785A (en)
CN (1) CN1514844A (en)
AT (1) ATE399794T1 (en)
BR (1) BR0207020A (en)
CA (1) CA2437287A1 (en)
DE (1) DE60227367D1 (en)
ES (1) ES2309168T3 (en)
HU (1) HUP0402041A2 (en)
MX (1) MXPA03007002A (en)
PL (1) PL363501A1 (en)
RU (1) RU2003125641A (en)
WO (1) WO2002077034A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60332358D1 (en) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDE
JP2010530895A (en) * 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． Modified toxin
EP2268297A4 (en) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
WO2011109556A2 (en) 2010-03-04 2011-09-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
NZ603033A (en) 2010-04-01 2014-06-27 Pfenex Inc Methods for g-csf production in a pseudomonas host cell
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc Modified toxins

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272703A1 (en) * 1986-12-23 1988-06-29 Kyowa Hakko Kogyo Co., Ltd. Novel polypeptide
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO1998059244A1 (en) * 1997-06-20 1998-12-30 Eclagen Limited Identification of mhc binding peptides
WO2000034317A2 (en) * 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272703A1 (en) * 1986-12-23 1988-06-29 Kyowa Hakko Kogyo Co., Ltd. Novel polypeptide
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO1998059244A1 (en) * 1997-06-20 1998-12-30 Eclagen Limited Identification of mhc binding peptides
WO2000034317A2 (en) * 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALTUVIA Y ET AL: "RANKING POTENTIAL BINDING PEPTIDES TO MHC MOLECULES BY A COMPUTATIONAL THREADING APPROACH", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 249, no. 1, 1995, pages 244 - 250, XP000925520, ISSN: 0022-2836 *
BOEHM H-J: "PREDICTION OF BINDING CONSTANTS OF PROTEIN LIGANDS: A FAST METHOD FOR THE PRIORITIZATION OF HITS OBTAINED FROM DE NOVO DESIGN OR 3D DATABASE SEARCH PROGRAMS", JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, ESCOM SCIENCE PUBLISHERS BV, XX, vol. 4, no. 12, July 1998 (1998-07-01), pages 309 - 323, XP008004781, ISSN: 0920-654X *
BRUSIC VLADIMIR ET AL: "MHCPEP, a database of MHC-binding peptides: Update 1997.", NUCLEIC ACIDS RESEARCH, vol. 26, no. 1, 1 January 1998 (1998-01-01), pages 368 - 371, XP002204283, ISSN: 0305-1048 *
LARICCHIA-ROBBIO LEOPOLDO ET AL: "Naturally occurring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum.", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 173, no. 2, November 1997 (1997-11-01), pages 219 - 226, XP002206160, ISSN: 0021-9541 *
SALI A ET AL: "COMPARATIVE PROTEIN MODELLING BY SATISFACTION OF SPATIAL RESTRAINTS", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 234, 1993, pages 779 - 815, XP002948615, ISSN: 0022-2836 *

Also Published As

Publication number Publication date
PL363501A1 (en) 2004-11-29
ES2309168T3 (en) 2008-12-16
EP1392731B1 (en) 2008-07-02
WO2002077034A2 (en) 2002-10-03
DE60227367D1 (en) 2008-08-14
KR20030074785A (en) 2003-09-19
CA2437287A1 (en) 2002-10-03
MXPA03007002A (en) 2003-11-18
EP1392731A2 (en) 2004-03-03
CN1514844A (en) 2004-07-21
US7392141B2 (en) 2008-06-24
US20040062749A1 (en) 2004-04-01
RU2003125641A (en) 2005-03-10
HUP0402041A2 (en) 2005-01-28
BR0207020A (en) 2004-06-22
JP2004527243A (en) 2004-09-09
ATE399794T1 (en) 2008-07-15

Similar Documents

Publication Publication Date Title
WO2002074783A3 (en) Modified interferon beta with reduced immunogenicity
WO2002062832A3 (en) Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
WO2002062843A3 (en) Modified erythropoietin (epo) with reduced immunogenicity
WO2000055345A3 (en) Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
WO2002062833A3 (en) Modified leptin with reduced immunogenicity
IL212076A (en) Isolated ifn-a polypeptides, method for their preparation, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for interferon therapy
WO2002085941A3 (en) Modified interferon alpha with reduced immunogenicity
WO2002070548A3 (en) Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity
BR0207283A (en) Reduced immunogenicity modified anti-egfr antibodies
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
WO2003040398A3 (en) Proteins stabilized with polysaccharide gums
WO1999033522A8 (en) Use of a phosphatidylserine/polypeptide conjugate for inducing autoimmunity in the treatment of cancer
WO2002070698A3 (en) Modified ciliary neurotrophic factor (cntf) with reduced immunogenicity
WO2002077034A3 (en) Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
BR0207014A (en) Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity.
WO2020226854A3 (en) Tolerogenic artificial antigen-presenting cells
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
WO2002068469A3 (en) Modified thrombopoietin with reduced immunogenicity
WO2003037272A3 (en) Thymosin alpha 1 peptide/polymer conjugates
DK1173476T3 (en) Functional soybean proteins
ATE515258T1 (en) MUCOSALIC ADMINISTRATION SYSTEM
BR0207905A (en) Modified protamine with reduced immunogenicity
WO2002074808A3 (en) Modified insulin with reduced immunogenicity
HUP0400340A2 (en) Methods for reducing immunogenicity of polypeptides
WO2003093298A3 (en) Immunogenic peptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002727320

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2437287

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/007002

Country of ref document: MX

Ref document number: 10467396

Country of ref document: US

Ref document number: 1020037010307

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002576292

Country of ref document: JP

Ref document number: 02804620X

Country of ref document: CN

Ref document number: 2002257579

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003/06931

Country of ref document: ZA

Ref document number: 200306931

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 1020037010307

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002727320

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002727320

Country of ref document: EP